

Raymond P. Ward proposes the following substitute bill:

Prescription Medication Amendments

2026 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Raymond P. Ward

Senate Sponsor: Evan J. Vickers

LONG TITLE

General Description:

This bill address prescription requirements.

Highlighted Provisions:

This bill:

- removes a requirement that a pharmacy notify a provider if the pharmacy substitutes the medication as authorized by the prescription;
- allows a prescription refill to remain valid for two years;
- addresses standing prescription drug orders issued by the Department of Health and Human Services; and
- makes technical and conforming changes.

Money Appropriated in this Bill:

None

Other Special Clauses:

None

Utah Code Sections Affected:

AMENDS:

58-17b-605, as last amended by Laws of Utah 2024, Chapter 507

58-17b-609, as last amended by Laws of Utah 2020, Chapter 310

ENACTS:

26B-4-516, Utah Code Annotated 1953

Be it enacted by the Legislature of the state of Utah:

Section 1. Section **26B-4-516** is enacted to read:

26B-4-516 . Standing prescription drug order issued by the department.

(1) The department may only issue a standing prescription drug order if the prescription:

- (a) is limited to a clearly defined clinical indication;
- (b) is for a diagnosis for which the medication has been approved by the federal Food and Drug Administration; and
- (c) is clinically appropriate.

Section 2. Section **58-17b-605** is amended to read:

58-17b-605 . Drug product equivalents and similar drug products.

(1) For the purposes of this section:

- (a)(i) "Drug" is as defined in Section 58-17b-102.
- (ii) "Drug" includes a "biological product" as defined in Section 58-17b-605.5.
- (b) "Drug product equivalent" means [a] a drug product that is designated as the therapeutic equivalent of another drug product in the Approved Drug Products with Therapeutic Equivalence Evaluations prepared by the Center for Drug Evaluation and Research of the United States Food and Drug Administration.
- (c) "Osteopathic Physician and Surgeon's Licensing Board" means the board created in Section 58-68-201.
- (d) "Medical Licensing Board" means the board created in Section 58-67-201.
- (e) "Therapeutically similar drug product" means a drug product that:
 - (i) provides a similar level of therapeutic benefit and risk to a patient as another drug product; and
 - (ii) is on the list of therapeutically similar drugs created by the division in accordance with Subsection (9).

(2) A pharmacist or pharmacy intern dispensing a prescription order for a specific drug by brand or proprietary name may substitute:

- (a) a drug product equivalent for the prescribed drug if:
 - (i) the purchaser specifically requests or consents to the substitution of a drug product equivalent;
 - (ii) the drug product equivalent is of the same generic type and is designated the therapeutic equivalent in the approved drug products with therapeutic equivalence evaluations prepared by the Center for Drug Evaluation and Research of the Federal Food and Drug Administration;
 - (iii) the drug product equivalent is permitted to move in interstate commerce;
 - (iv) the pharmacist or pharmacy intern counsels the patient on the use and the expected response to the prescribed drug, whether a substitute or not;
 - (v) the substitution is not otherwise prohibited by law; and

63 (vi) the prescribing practitioner has not indicated that a drug product equivalent may
64 not be substituted for the drug, as provided in Subsection (6); or
65 (b) a therapeutically similar drug product if:
66 (i) the prescriber has written "similar substitution authorized" on the prescription for
67 the prescribed drug;
68 (ii) the therapeutically similar drug product is listed on the therapeutically similar
69 drug list described in Subsection (9) as a drug that can be substituted for the
70 prescribed drug;
71 (iii) the purchaser specifically requests or consents to the substitution of the
72 therapeutically similar drug;
73 (iv) the dispensed therapeutically similar drug product is permitted to move in
74 interstate commerce;
75 (v) the pharmacist or pharmacy intern counsels the patient on the use and the
76 expected response to the therapeutically similar drug product;
77 (vi) the substitution is not otherwise prohibited by law; and
78 (vii) the substitution:
79 (A) results in a decreased cost to the patient;
80 (B) is covered on the patient's health benefit plan formulary as a preferred drug or
81 at the same or lower payment tier;
82 (C) is necessary because the pharmacist does not have the originally prescribed
83 medication available to dispense to the patient; or
84 (D) would be beneficial to the patient for any reason if the patient and pharmacist
85 mutually agree that the substitution would benefit the patient.

86 (3)(a) Each out-of-state mail service pharmacy dispensing a drug product equivalent or a
87 therapeutically similar drug product as a substitute for another drug into this state
88 shall notify the patient of the substitution either by telephone or in writing.
89 (b) Each out-of-state mail service pharmacy shall comply with the requirements of this
90 chapter with respect to a drug product equivalent or a therapeutically similar drug
91 product substituted for another drug, including labeling and record keeping.

92 (4)[(a)] Pharmacists or pharmacy interns may not substitute without the prescriber's
93 authorization on trade name drug product prescriptions unless the product is currently
94 categorized in the approved drug products with therapeutic equivalence evaluations
95 prepared by the Center for Drug Evaluation and Research of the [Federal] United
96 States Food and Drug Administration as a drug product considered to be

97 therapeutically equivalent to another drug product.

98 [~~(b) A pharmacist or pharmacy intern that substitutes a drug product for a therapeutically~~
99 ~~similar drug product under Subsection (2)(b), for any prescription intended to last~~
100 ~~longer than 30 days, shall notify the prescriber that the pharmacist or pharmacy intern~~
101 ~~substituted the drug.]~~

102 (5) A pharmacist or pharmacy intern who dispenses a prescription with a drug product
103 equivalent or a therapeutically similar drug product under this section assumes no
104 greater liability than would be incurred had the pharmacist or pharmacy intern dispensed
105 the prescription with the drug product prescribed.

106 (6)(a) If, in the opinion of the prescribing practitioner, it is in the best interest of the
107 patient that a drug product equivalent not be substituted for a prescribed drug, the
108 practitioner may indicate a prohibition on substitution either by writing "dispense as
109 written" or signing in the appropriate space where two lines have been preprinted on
110 a prescription order and captioned "dispense as written" or "substitution permitted".

111 (b) If the prescription is communicated orally by the prescribing practitioner to the
112 pharmacist or pharmacy intern, the practitioner shall indicate the prohibition on
113 substitution and that indication shall be noted in writing by the pharmacist or
114 pharmacy intern with the name of the practitioner and the words "orally by" and the
115 initials of the pharmacist or pharmacy intern written after it.

116 (7)(a) A pharmacist or pharmacy intern who substitutes a drug product equivalent or
117 therapeutically similar drug product for a prescribed drug shall communicate the
118 substitution to the purchaser.

119 (b) The drug product equivalent or therapeutically similar drug product container shall
120 be labeled with the name of the drug dispensed.

121 (c) The pharmacist, pharmacy intern, or pharmacy technician shall indicate on the file
122 copy of the prescription both the name of the prescribed drug and the name of the
123 drug product equivalent or the therapeutically similar drug product dispensed in place
124 of the prescribed drug.

125 (8)(a) For purposes of this Subsection (8), "substitutes" means to substitute:

- 126 (i) a generic drug for another generic drug;
- 127 (ii) a generic drug for a nongeneric drug;
- 128 (iii) a nongeneric drug for another nongeneric drug; or
- 129 (iv) a nongeneric drug for a generic drug.

130 (b) A prescribing practitioner who makes a finding under Subsection (6)(a) for a patient

131 with a seizure disorder shall indicate a prohibition on substitution of a drug product
132 equivalent in the manner provided in Subsection (6)(a) or (b).

133 (c) Except as provided in Subsection (8)(d), a pharmacist or pharmacy intern who cannot
134 dispense the prescribed drug as written, and who needs to substitute a drug product
135 equivalent for the drug prescribed to the patient to treat or prevent seizures shall
136 notify the prescribing practitioner [prior to] before the substitution.

137 (d) Notification under Subsection (8)(c) is not required if the drug product equivalent is
138 paid for in whole or in part by Medicaid.

139 (9)(a) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act,
140 and in consultation with the board and the Medical Licensing Board , the division
141 shall create a therapeutically similar drug product list that contains lists of drug
142 products that are therapeutically similar to each other.

143 (b) The division may not add a drug product to the therapeutically similar drug product
144 list if the addition is opposed by:
145 (i) the board; or
146 (ii) the Medical Licensing Board.

147 (c) When considering a drug to be added to the therapeutically similar drug product list,
148 the division shall consult with each board described in Subsection (9)(b).

149 (d) When consulting with the division under Subsection (9)(c), a board described in
150 Subsection (9)(b) may:
151 (i) review clinical practice guidelines;
152 (ii) review peer-reviewed studies; and
153 (iii) consult with medical specialists who are familiar with the drug under
154 consideration.

155 (e) When creating the therapeutically similar drug product list, before considering any
156 other types of drugs, the division shall consider:
157 (i) albuterol inhalers;
158 (ii) injectable forms of insulin; and
159 (iii) diabetic test strips.

160 (f) The division may, in consultation with each board described in Subsection (9)(b),
161 create standards in rule for considering drug products that should be added to the
162 therapeutically similar drug product list.

163 (10) Failure of a licensed medical practitioner to specify that no substitution is authorized
164 does not constitute evidence of negligence.

165 Section 3. Section **58-17b-609** is amended to read:

166 **58-17b-609 . Limitation on prescriptions and refills -- Controlled Substances Act**

167 **not affected -- Legend drugs.**

168 (1) Except as provided in Sections 58-16a-102 and 58-17b-608.2, a prescription for any
169 prescription drug or device may not be dispensed after one year from the date it was
170 initiated except as otherwise provided in Chapter 37, Utah Controlled Substances Act.

171 (2) Except as provided in Section 58-17b-608.2, a prescription authorized to be refilled may
172 not be refilled after [one year] two years from the original issue date.

173 (3) A practitioner may not be prohibited from issuing a new prescription for the same drug
174 orally, in writing, or by electronic transmission.

175 (4) Nothing in this chapter affects Chapter 37, Utah Controlled Substances Act.

176 (5) A prescription for a legend drug written by a licensed prescribing practitioner in another
177 state may be filled or refilled by a pharmacist or pharmacy intern in this state if the
178 pharmacist or pharmacy intern verifies that the prescription is valid.

179 **Section 4. Effective Date.**

180 This bill takes effect on May 6, 2026.